# Cresco Labs Inc.: overview CRLBF · OTC · CIK 1832928 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/crlbf.md) · [Financials](/companies/crlbf/financials.md) · [Filings](/companies/crlbf/filings.md) · [Insiders](/companies/crlbf/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [822](/filings/0001832928-23-000003.md) | [843](/filings/0001832928-24-000024.md) | [771](/filings/0001832928-25-000006.md) | [724](/filings/0001832928-26-000005.md) | [656](/filings/0001832928-26-000005.md) | | Gross margin | % | [49.5%](/filings/0001832928-23-000003.md) | [48.3%](/filings/0001832928-24-000024.md) | [47.0%](/filings/0001832928-25-000006.md) | [50.3%](/filings/0001832928-26-000005.md) | [49.5%](/filings/0001832928-26-000005.md) | | Operating margin | % | [(26.5%)](/filings/0001832928-23-000003.md) | [(10.0%)](/filings/0001832928-24-000024.md) | [(11.4%)](/filings/0001832928-25-000006.md) | [14.8%](/filings/0001832928-26-000005.md) | [(4.3%)](/filings/0001832928-26-000005.md) | | Net margin | % | [(38.9%)](/filings/0001832928-23-000003.md) | [(25.2%)](/filings/0001832928-24-000024.md) | [(22.8%)](/filings/0001832928-25-000006.md) | [(10.3%)](/filings/0001832928-26-000005.md) | [(20.6%)](/filings/0001832928-26-000005.md) | | Diluted EPS | $ per share | [(1.22)](/filings/0001832928-23-000003.md) | [(0.71)](/filings/0001832928-24-000024.md) | [(0.54)](/filings/0001832928-25-000006.md) | [(0.22)](/filings/0001832928-26-000005.md) | [(0.38)](/filings/0001832928-26-000005.md) | | Free cash flow | $m | [(79.4)](/filings/0001832928-23-000003.md) | [(64.3)](/filings/0001832928-24-000024.md) | [3.2](/filings/0001832928-25-000006.md) | [113](/filings/0001832928-26-000005.md) | [37.8](/filings/0001832928-26-000005.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue; Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue; Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue; Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/crlbf/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [ALBERT D MASON INC](/funds/1169318.md) | 2026-06-30 | $73.1k | 88,035 | | Unchanged | | [Ancora Advisors LLC](/funds/1446114.md) | 2026-06-30 | $39.6k | 48,028 | | Reduced −12,141 | | [Strategic Investment Solutions, Inc. /IL](/funds/1960144.md) | 2026-06-30 | $1.2k | 1,408 | | Unchanged | | [THOMPSON INVESTMENT MANAGEMENT, INC.](/funds/1277279.md) | 2026-06-30 | $602 | 725 | | Unchanged | | [MassMutual Private Wealth & Trust, FSB](/funds/1103653.md) | 2026-06-30 | $166 | 200 | | Unchanged | | [Sterling Capital Management LLC](/funds/1329883.md) | 2026-06-30 | $110 | 132 | | New +132 | | [HANTZ FINANCIAL SERVICES, INC.](/funds/1071061.md) | 2026-06-30 | $8 | 9,509 | | Added +489 | ## Recent filings [All 89 filings](/companies/crlbf/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-13 | 17:15 ET | [6-K](/filings/0001832928-26-000014.md) | Report of a foreign private issuer, period 2026-10-13 | 0001832928-26-000014 | | 2026-09-30 | 16:29 ET | [6-K](/filings/0001832928-26-000012.md) | Report of a foreign private issuer, period 2026-09-30 | 0001832928-26-000012 | | 2026-08-06 | 11:45 ET | [6-K](/filings/0001832928-26-000010.md) | Report of a foreign private issuer, period 2026-06-30 | 0001832928-26-000010 | | 2026-05-08 | 11:51 ET | [6-K](/filings/0001832928-26-000008.md) | Report of a foreign private issuer, period 2026-03-31 | 0001832928-26-000008 | | 2026-03-06 | 22:35 ET | [40-F](/filings/0001832928-26-000005.md) | Annual report of a Canadian issuer, period 2025-12-31 | 0001832928-26-000005 | | 2026-02-02 | 23:19 ET | [6-K](/filings/0001832928-26-000003.md) | Report of a foreign private issuer, period 2026-01-30 | 0001832928-26-000003 | | 2025-11-07 | 22:21 ET | [6-K](/filings/0001832928-25-000038.md) | Report of a foreign private issuer, period 2025-11-07 | 0001832928-25-000038 | | 2025-09-22 | 16:46 ET | [6-K](/filings/0001832928-25-000028.md) | Report of a foreign private issuer, period 2025-09-22 | 0001832928-25-000028 | | 2025-09-17 | 22:48 ET | [6-K](/filings/0001832928-25-000024.md) | Report of a foreign private issuer, period 2025-09-16 | 0001832928-25-000024 | | 2025-08-15 | 15:18 ET | [6-K](/filings/0001832928-25-000018.md) | Report of a foreign private issuer, period 2025-08-15 | 0001832928-25-000018 | ## Latest annual report [Form 40-F for the fiscal year ended Dec 31, 2025](/filings/0001832928-26-000005.md), filed Mar 6, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1832928 - Tickers: CRLBF - Exchange: OTC - SIC code: 2833 Medicinal Chemicals & Botanical Products - State of incorporation: A1 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.